Xin Wei, Zhao Chaoran, Jiang Longyang, Pei Dongmei, Zhao Lin, Zhang Chengpu
Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, China.
Liaoning Key Laboratory of Molecular Targeted Anti-tumor Drug Development and Evaluation China Medical University, Shenyang, China.
Pathol Oncol Res. 2021 Mar 29;27:585192. doi: 10.3389/pore.2021.585192. eCollection 2021.
Head and neck squamous cell cancer (HNSCC) is one of the most common types of cancer worldwide. There have been many reports suggesting that biomarkers explored via database mining plays a critical role in predicting HNSCC prognosis. However, a single biomarker for prognostic analysis is not adequate. Additionally, there is growing evidence indicating that gene signature could be a better choice for HNSCC prognosis. We performed a comprehensive analysis of mRNA expression profiles using clinical information of HNSCC patients from The Genome Atlas (TCGA). Gene Set Enrichment Analysis (GSEA) was performed, and we found that a set of genes involved in epithelial mesenchymal transition (EMT) contributed to HNSCC. Cox proportional regression model was used to identify a four-gene () signature that were significantly associated with overall survival (OS), and all the four genes were significantly upregulated in tumor tissues. We successfully classified the patients with HNSCC into high-risk and low-risk groups, where in high-risk indicated poorer patient prognosis, indicating that this gene signature might be a novel potential biomarker for the prognosis of HNSCC. The prognostic ability of the gene signature was further validated in an independent cohort from the Gene Expression Omnibus (GEO) database. In conclusion, we identified a four-EMT-based gene signature which provides the potentiality to serve as novel independent biomarkers for predicting survival in HNSCC patients, as well as a new possibility for individualized treatment of HNSCC.
头颈部鳞状细胞癌(HNSCC)是全球最常见的癌症类型之一。已有许多报告表明,通过数据库挖掘探索的生物标志物在预测HNSCC预后中起着关键作用。然而,单一的生物标志物用于预后分析是不够的。此外,越来越多的证据表明,基因特征可能是HNSCC预后的更好选择。我们使用来自癌症基因组图谱(TCGA)的HNSCC患者临床信息对mRNA表达谱进行了全面分析。进行了基因集富集分析(GSEA),我们发现一组参与上皮-间质转化(EMT)的基因促成了HNSCC。使用Cox比例回归模型确定了一个与总生存期(OS)显著相关的四基因()特征,并且所有这四个基因在肿瘤组织中均显著上调。我们成功地将HNSCC患者分为高风险和低风险组,其中高风险表明患者预后较差,这表明该基因特征可能是HNSCC预后的一种新型潜在生物标志物。该基因特征的预后能力在来自基因表达综合数据库(GEO)的独立队列中得到了进一步验证。总之,我们确定了一个基于EMT的四基因特征,它有潜力作为预测HNSCC患者生存的新型独立生物标志物,也为HNSCC的个体化治疗提供了新的可能性。